More on Celgene (CELG +1.8%) Q3: net profit +14% to $424.2M. Revlimid (blood-cancer) +18% to...

|About: Celgene Corporation (CELG)|By:, SA News Editor

More on Celgene (CELG +1.8%) Q3: net profit +14% to $424.2M. Revlimid (blood-cancer) +18% to $970M, Vidaza (Blood cancer) +15% to $220M despite loss of patent protection in 2011. Raises FY EPS estimate to $4.85-$4.90 from increased July estimate of $4.80-$4.85 and vs consensus of $4.88; narrows revenue guidance to $5.45B-$5.55B vs consensus of $5.5B.